Supreme Court Urged To Deny Saw Palmetto Health Claim Review
This article was originally published in The Tan Sheet
The Supreme Court should refuse to consider the appropriateness of a proposed saw palmetto/prostatic hyperplasia health claim due to the petitioners' misinterpretation of the FD&C Act, Acting Solicitor General Paul Clemente maintains
You may also be interested in...
The Washington, D.C. federal appeals court upheld FDA's denial of a health claim petition linking saw palmetto extract to treatment of benign prostatic hypertrophy
FDA's decision to deny a health claim linking saw palmetto extract to the treatment of benign prostatic hypertrophy symptoms was upheld by a Washington, D.C. federal court in a Jan. 3 decision
FDA's denial of a health claim relating to saw palmetto and benign prostatic hyperplasia violates the First Amendment, the Nutrition Labeling & Education Act (NLEA) and the Administrative Procedures Act (APA), Washington, D.C.-based Emord & Associates asserts in a suit filed Dec. 7.